Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation

Conditions:   Cholangiocarcinoma;   Chondrosarcoma;   GliomaIntervention:   Drug: AG881Sponsor:   Agios Pharmaceuticals, Inc.Recruiting - verified June 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials